Abstract
L19SIP (small immunoprotein, 80 kDa) is a recombinant, fully human antibody fragment against fibronectin extradomain B (EDB), a highly selective marker of tumor neovasculature. The radiolabeled 131I-L19SIP is designed for radioimmunotherapy (RIT). This Phase 1, first-in-human trial evaluates the dosimetry, safety, and anti-tumor effects of 131I-L19SIP.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
